|
|
 |
 |
| |
 Version imprimable |
Erythroderma in the era of biological therapies |
European Journal of Dermatology. Volume 22, Numéro 2, 167-71, March-April 2012, Review article
|
 Free Article
|
Auteur(s) : Edoardo Zattra, Anna Belloni Fortina, Andrea Peserico, Mauro Alaibac |
Résumé : Erythroderma is a scaling erythematous dermatitis involving 90% or more of the cutaneous surface. Psoriasis and eczema are the most common dermatoses underlying erythroderma. Cutaneous T cell lymphomas can also cause erythroderma. Differential diagnosis between psoriatic erythroderma and lymphomatous erythroderma is often challenging. Tumour necrosis factor-alpha inhibitors are a new class of drugs used in the treatment of psoriasis, even in erythrodermic psoriasis. The effects of anti-tumour necrosis factor-alpha in cutaneous T cell lymphomas have not yet been established. Consequently, it is mandatory to treat an erythrodermic psoriatic patient with tumour necrosis factor-alpha blockers only if a lymphoproliferative cutaneous disorder has been excluded. |
Mots-clés : |
|
